Revenue growth reached 123.7% in 2025Q3, though underwriting profitability remains highly volatile, evidenced by a combined ratio that swung from 26.4% in 2023Q2 to 150.5% in 2024Q4.
| Revenue | 196.55M | 111.92M | 66.4M | 44.71M | 22.59M | 1.22M |
| Revenue Growth % | 91.93% | 68.56% | 48.5% | 97.92% | 1744.73% | - |
| Medical Costs & Claims | 24.54M | 11.37M | 6.49M | 5.88M | 14.21M | 514.67K |
| Medical Cost Ratio % | 12.48% | 10.16% | 9.77% | 13.16% | 62.88% | 42.02% |
| Gross Profit | 172.01M | 100.55M | 59.91M | 38.83M | 8.39M | 710.01K |
| Gross Margin % | 87.52% | 89.84% | 90.23% | 86.84% | 37.12% | 57.98% |
| Gross Profit Growth % | - | 67.84% | 54.3% | 362.98% | 1081.22% | - |
| Operating Expenses | 122.82M | 101.44M | 35.79M | 5.16M | 7.45M | -641.33K |
| OpEx / Revenue % | 62.49% | 90.63% | 53.89% | 11.55% | 32.97% | -52.37% |
| Depreciation & Amortization | 17.08M | 7.91M | 3.41M | 4.28K | 31.24K | 0 |
| Combined Ratio % | 74.97% | 100.79% | 63.67% | 24.71% | 95.85% | -10.34% |
| Operating Income | 49.2M | -888.3K | 24.13M | 33.67M | 937.12K | 1.35M |
| Operating Margin % | 25.03% | -0.79% | 36.33% | 75.29% | 4.15% | 110.34% |
| Operating Income Growth % | - | -103.68% | -28.34% | 3492.44% | -30.65% | - |
| EBITDA | 66.27M | 7.02M | 27.54M | 33.67M | 968.36K | 662.02K |
| EBITDA Margin % | 33.72% | 6.27% | 41.47% | 75.3% | 4.29% | 54.06% |
| Interest Expense | 33.97M | 18.28M | 9.87M | 42.8K | 0 | 0 |
| Non-Operating Income | -9.75M | 265.31K | 3.76M | 345.54K | -61.5K | 689.33K |
| Pretax Income | 24.98M | -19.43M | 10.5M | 33.28M | 998.62K | 662.02K |
| Pretax Margin % | 12.71% | -17.36% | 15.82% | 74.42% | 4.42% | 54.06% |
| Income Tax | 13.9M | 5.48M | 1.47M | 889.94K | 1.2K | 1.56K |
| Effective Tax Rate % | 55.65% | -28.22% | 13.98% | 2.67% | 0.12% | 0.24% |
| Net Income | 11.04M | -23.96M | 9.52M | 31.68M | 997.41K | 662.02K |
| Net Margin % | 5.62% | -21.41% | 14.33% | 70.86% | 4.41% | 54.06% |
| Net Income Growth % | 192.58% | -351.78% | -69.96% | 3076.44% | 50.66% | - |
| EPS (Diluted) | 0.11 | -0.34 | 0.16 | -0.02 | 0.37 | -0.25 |
| EPS Growth % | 152% | -312.5% | 833.94% | -105.89% | 248% | - |
| EPS (Basic) | - | -0.34 | 0.17 | -0.02 | 0.37 | -0.25 |
| Diluted Shares Outstanding | 96.65M | 70.76M | 57.77M | 29.55M | 43.13M | 43.13M |
Fair value accounting volatility
As reported in recent financial statements, Abacus Life achieved a 123.7% year-over-year revenue growth in 2025Q3, signaling an aggressive scaling of its policy origination platform that significantly outpaces the more moderate growth rates observed in the broader specialty finance and alternative asset management peer group.
The rapid top-line expansion suggests that the company is successfully leveraging its direct-to-consumer model to capture market share in the life settlement space. However, investors should monitor whether this growth is sustainable or if it relies on increasingly expensive customer acquisition costs that could pressure future margins.
Based on the company's reported figures, the combined ratio fluctuated significantly from a low of 26.4% in 2023Q2 to a peak of 150.5% in 2024Q4, indicating that underwriting profitability is currently inconsistent and highly sensitive to the timing of policy maturities and fair value adjustments.
The wide variance in the combined ratio suggests that Abacus Life's core underwriting performance is not yet stabilized, likely due to the lumpy nature of life settlement cash flows. The 2024Q4 spike above 100% highlights the inherent risk in the business model where operational costs can quickly overwhelm premium-related income during periods of lower maturity activity.
According to recent SEC filings, the company's transition to a publicly traded entity has coincided with heightened earnings volatility, as evidenced by the swing from a $18.3M net loss in 2024Q4 to a $7.1M net profit in 2025Q3, reflecting the impact of fair value accounting.
This period of transition appears to have exposed the company to greater quarterly scrutiny, where non-cash fair value adjustments create significant noise in the bottom line. Analysts should interpret these swings as a reflection of portfolio revaluation rather than a fundamental shift in the underlying cash-generating capability of the life settlement assets.
As indicated by the discrepancy between net income and operational performance, the reliance on ASC 820 fair value accounting may be masking the true liquidity profile of the firm, as non-cash unrealized gains often drive headline earnings while mandatory premium payments represent a persistent cash outflow.
Investors should be cautious of the reported net income figures, as they may not accurately represent the company's ability to service its 9.875% senior notes. The persistent gap between accounting profit and cash flow warrants further investigation into the sustainability of the current debt-to-equity structure as the portfolio scales.
Quick answers to the most common questions about buying ABLLL stock.
For fiscal year 2024, Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) reported total revenue of $111.9M. This represents a 9039.0% increase compared to $1.2M in 2020.
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) reported a net loss of $24.0M for the fiscal year ending 2024.
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) reported an operating income of $-0.9M, resulting in an operating profit margin of -0.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028 (ABLLL) generated $100.6M in gross profit for the year, representing a gross profit margin of 89.8%. This demonstrates the company's core pricing power and production efficiency.